| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented plans for a registrational program for zervimesine in mild-to-moderate Alzheimer's disease during the annual Clinical Trials on Alzheimer's Disease (CTAD) conference. Cognition discussed the program design with the U.S. Food and Drug Administration (FDA) during an end-of-Phase 2 meeting. The CTAD poster will be available on the Publications page of the company website in accordance with the conference embargo policy.
The Phase 3 program is expected to enroll adults with mild-to-moderate Alzheimer's disease who have lower levels of plasma p-tau217 at screening. Based on Phase 2 clinical study results, the Company believes that screening for p-tau217 levels will enrich the study population with patients most likely to benefit from zervimesine treatment. The U.S. Food and Drug Administration agreed with this approach during the July 2025 end-of-Phase 2 meeting.
Posted In: CGTX
